secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neuronetics, Inc. (STIM)
CIK:        0001227636
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001558370-22-016742
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neuronetics Q3 revenue $16.5M (+20% YoY); raises FY2022 guidance to $63-64M
---------------------------------------------------------------------------

- Q3 revenue $16.5M (+20% YoY); net loss $(7.6)M ($0.28/sh) vs $(8.2)M loss a year ago.
- Record US treatment session revenue $11.9M (+16% YoY); NeuroStar system revenue up 51% to $3.9M.
- Raised FY2022 revenue guidance to $63-64M from $60-62M; Q4 expected $16-17M.
- Received FDA 510(k) clearance for D-Tect MT Accessory; positive TMS coverage policies from CGS and NGS MACs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/0001558370-22-016742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1227636/000155837022016742/stim-20221108x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-016742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer